CLS Holdings USA (OTCMKTS: CLSH) inked a collaborative agreement with Herbal Edibles Inc to manufacture each other’s brands and distribute them in New Mexico and Nevada. 

Reports highest revenues in a single month

Under the new venture, CLS will introduce its branded products in markets other than Nevada. It is on the backdrop of significant success in its City Trees brand after the relaunch in September 2020. The company recently reported higher revenues from its City Trees brand in a single month – March 2021. 

Market penetration at 45%

Herbal Edibles branded products reported a market penetration of 45% in New Mexico as of April 2021. CLS plans to benefit by improving its market penetration of City Trees products in New Mexico. 

CLS will improve its infrastructure and provide additional resources to increase sales in New Mexico. The company plans to unveil its tincture products in May 2021 in this flourishing market. 

In return, Herbal Edibles will share its recipes for some of the items in the product line of non-GMO and organic edible products.

Cannabics Pharmaceuticals Inc (OTCMKTS: CNBX) gets patent notice of allowance from IMPI

Cannabics Pharmaceuticals Inc (OTCMKTS: CNBX) is excited to announce the receipt of patent “notice of allowance” from IMPI (Mexican Patent and Trademark Office) for its patent called System and Method to increase the throughput of cancer cells screening. It is on the backdrop of EPO (European Patent Office) intention to provide European Patent to Cannabics.

Cannabics’s CEO, Eyal Barad, said the patent application is an example of its novel and innovative approach to drug discovery in its field. The company already received the patent in South Africa and Israel. 

Develops a drug to treat Melanoma

Cannabics introduced a new research program to develop a new drug to cure Melanoma. It follows the recent development of a proprietary formula – Cannabics RCC-33 to cure Colorectal Cancer. The drug helped to reduce tumour volume by 33% and improved survival rate by 35% in in-vivo experiments conducted on mice.  

Cannabics’s COO, Gabriel Yariv, said the company would utilize the expertise and experience to develop innovative drugs targeting tumours using its in-house drug discovery platform. The company could develop an anti-tumour drug to treat melanoma. It reported high-quality preclinical data and detected several promising discoveries for further investigation.